Yahoo Finance 
Angina Pectoris Drugs Global Market Report 2023
Major players in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca Plc, Amgen Inc., Gilead Sciences Inc., Bausch Health Companies Inc., Merck & Co. Inc., Eli Lilly and Company, Otsuka Pharmaceutical Co.
New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Angina Pectoris Drugs Global Market Report 2023" - https://www.reportlinker.com/p06486577/?utm_source=GNW
Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AbbVie Inc., Sun Pharmaceutical Industries Limited., and F. Hoffmann-La Roche AG.
The global angina pectoris drugs market is expected to grow from $11.20 billion in 2022 to $11.82 billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The angina pectoris drugs market is expected to reach $14.50 billion in 2027 at a CAGR of 5.2%.
The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.
The value of goods in this market includes related services sold by the creators of the goods.
Angina pectoris drugs are medications used to treat angina pectoris, a medical illness that causes chest pain or discomfort when a portion of the heart does not receive enough blood and oxygen. Angina pectoris drugs treat chest pain or discomfort due to coronary heart disease.
North America was the largest region in the angina pectoris drugs market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in angina pectoris drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main drugs of angina pectoris drugs are nitrates, antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other drugs.Nitrates and nitrites are nitrogen and oxygen atom-containing chemicals.
Nitrates are frequently used to treat angina pectoris, a condition that involves chest pain or discomfort caused by decreased blood supply to the heart.The indications include stable angina, unstable angina, and prinzmetal’s angina.
The angina pectoris drugs are administered via oral, parenteral, transdermal, other route of administrations that are used by hospitals, homecare, specialty clinics, other end users.
The increasing prevalence of chronic angina pectoris is expected to propel the growth of the angina pectoris drug market going forward.Chronic angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle.
Angina pectoris drugs are vital in treating chronic angina.They can provide several benefits to those suffering from this illness, including coronary heart disease, cardiovascular disease, high blood pressure, and being overweight or obese.
For instance, in May 2023, according to the Centers for Disease Control and Prevention Highlights, a US-based intergovernmental organization, coronary heart disease killed round 375,476 people in 2021 where, roughly one in every twenty people aged 20 and over (5%).Further, in 2021, almost 2 out of every 10 deaths from coronary artery disease are expected to occur in people under 65.
Furthermore, in December 2022, according to the National Library of Medicine, a national center for biological information, Angina affects more than 10 million people in the United States, with more than 500,000 new diagnoses each year. Therefore, the increasing prevalence of chronic angina pectoris is driving the growth of the angina pectoris drug market.
Product innovation is a key trend gaining popularity in angina pectoris drugs market.Major companies operating in the angina pectoris drug market are adopting new technologies to sustain their position in the market.
For instance, in March 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe.The Food and Drug Administration of the United States has authorized this product.
In hospitals, 10 mg/2 mL PFS is used to treat severe hypertension and lower blood pressure.
In November 2022, Alcon, a US-based pharmaceutical and medical device company, acquired Aerie Pharmaceuticals Inc. for an undisclosed amount. This acquisition broadens, diversifies, and enriches Alcon’s portfolio of commercial products and development pipeline, with a strong position in the ophthalmic pharmaceutical industry. Aerie Pharmaceuticals, Inc. is a US-based clinical-stage pharmaceutical company offering the angina pectoris drug.
The countries covered in the angina pectoris drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The angina pectoris drugs market research report is one of a series of new reports that provides angina pectoris drugs market statistics, including angina pectoris drugs industry global market size, regional shares, competitors with a angina pectoris drugs market share, detailed angina pectoris drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. This angina pectoris drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06486577/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
